The Readout Loud
Ein Podcast von STAT - Donnerstags
350 Folgen
-
268: Biogen's sticky situation, Wegovy's risks, & biotech insider trading
Vom: 27.7.2023 -
267: BridgeBio's big week, Lilly's Alzheimer's data, & succession at Stanford
Vom: 20.7.2023 -
266: Wegovy in the brain, pivotal Alzheimer's data, & pulling Threads
Vom: 13.7.2023 -
265: Novavax's CEO promises a turnaround & how Lilly roiled the obesity market
Vom: 29.6.2023 -
264: Messy PBM conflicts, debatable vaccines, & the future of flu season
Vom: 22.6.2023 -
263: Biogen's messy board, Laronde's data problem, & the downside of a boom
Vom: 15.6.2023 -
262: Merck v. USA, the best of ASCO, and Leqembi at the FDA
Vom: 8.6.2023 -
261: Fake medical devices, real cancer drugs, & curious Ozempic effects
Vom: 1.6.2023 -
260: ChatGPT in medicine, a boom in weight loss pills, & Sarepta at the FDA
Vom: 25.5.2023 -
259: The FTC v. Amgen, Sarepta's future, & Galapagos' turnaround
Vom: 18.5.2023 -
258: Pharma vs. PBMs, Sarepta at the FDA, & a bold idea gone awry
Vom: 11.5.2023 -
257: Lilly's Alzheimer's success, a milestone FDA approval, & Moderna's shrinking business
Vom: 4.5.2023 -
256: Explaining the E.U.'s pharma overhaul, Lilly's booming business, & a long-awaited drug approval
Vom: 27.4.2023 -
255: Sarepta's pivotal moment, biotech's big week, & the future of Covid boosters
Vom: 20.4.2023 -
254: The legal battle over abortion, an FDA 'bully pulpit' and Moderna's future
Vom: 13.4.2023 -
253: Illumina’s boardroom intrigue, the next big Alzheimer’s readout, & J&J’s creative lawyers
Vom: 6.4.2023 -
252: Biotech's monkey shortage, the broken generics market, & conference cancel culture
Vom: 30.3.2023 -
251: Bancel v. Bernie, Sarepta's FDA runaround, & Regeneron's ever-growing blockbuster
Vom: 23.3.2023 -
250: SVB's long biotech shadow, pushy AI algorithms, & Icahn v. Illumina
Vom: 16.3.2023 -
249: Robert Califf on how drugs get approved, plus the nascent revolution in obesity
Vom: 9.3.2023
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.